Marinus Pharmaceuticals Inc
(NASDAQ : MRNS)

( )
MRNS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SHPGShire PLC Sponsored ADR
0.24%178.580.4%$137.09m
PRGOPerrigo Co. Plc
0.48%73.346.8%$93.10m
JAZZJazz Pharmaceuticals Plc
0.68%163.032.2%$71.22m
MNKMallinckrodt Plc
-0.40%29.6721.1%$65.61m
ENDPEndo International Plc
0.13%15.968.9%$57.71m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.98%153.646.8%$51.91m
PTLAPortola Pharmaceuticals, Inc.
1.31%28.637.7%$39.01m
UTHRUnited Therapeutics Corporation
-0.27%125.8614.4%$38.69m
SAGESAGE Therapeutics, Inc.
-1.45%144.839.6%$36.37m
CTLTCatalent Inc
-0.33%42.742.4%$36.15m
ICPTIntercept Pharmaceuticals, Inc.
-1.03%119.3618.7%$32.09m
SUPNSupernus Pharmaceuticals, Inc.
2.13%47.906.2%$28.67m
PCRXPacira Pharmaceuticals, Inc.
7.32%51.3510.6%$27.64m
ZGNXZogenix, Inc.
-3.29%47.0510.0%$27.47m
MDCOMedicines Company
-0.18%33.6021.8%$24.49m

Company Profile

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.